EQS-News

NeuroRx and Relief announce topline efficacy data from patients treated with RLF-100(TM) (aviptadil) under the U.S. FDA Expanded Access Protocol authorization for respiratory failure related to critical COVID-19 - Seite 5

Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding AG, NeuroRx, Inc. and their businesses. The results reported herein may or may not be indicative of the results of future and larger clinical trials for RLF-100(TM) for the treatment of COVID-19. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding AG and/or NeuroRx, Inc. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

CORPORATE CONTACTS RELIEF THERAPEUTICS Holding AG Raghuram (Ram) Selvaraju, Ph.D., MBA      Chairman of the Board [e-mail]	MEDIA CONTACT Relief (Europe): Anne Hennecke / Brittney Sojeva MC Services AG [e-mail] [phone]
NeuroRx, Inc. Jonathan C. Javitt, M.D., MPH Chief Executive Officer NeuroRx, Inc. [e-mail]	NeuroRx (United States): David Schull Russo Partners, LLC [e-mail] 858-717-2310
	INVESTOR RELATIONS Relief (Europe): Anne Hennecke / Brittney Sojeva MC Services AG [e-mail] [phone]
	NeuroRx (United States): Brian Korb Solebury Trout [e-mail] 917-653-5122

---

End of Media Release

---

Language:	English
Company:	Relief Therapeutics Holdings AG
	Avenue de Sécheron 15
	1202 Genève
	Switzerland
E-mail:	[e-mail]
Internet:	https://relieftherapeutics.com
ISIN:	CH0100191136
Listed:	SIX Swiss Exchange
EQS News ID:	1140308